{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:29:13Z","timestamp":1762928953877,"version":"3.41.2"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiative Joint Undertaking","award":["115721-2"],"award-info":[{"award-number":["115721-2"]}]},{"name":"European Union\u2019s Seventh Framework Programme","award":["FP7\/2007-2013"],"award-info":[{"award-number":["FP7\/2007-2013"]}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inhaled antibiotics are a common and valuable therapy for patients suffering from chronic lung infection, with this particularly well demonstrated for patients with cystic fibrosis. However, in vitro tests to predict patient response to inhaled antibiotic therapy are currently lacking. There are indications that antimicrobial susceptibility testing (AST) may have a role in guidance of therapy, but which tests would correlate best still needs to be researched in clinical studies or animal models. Applying the principles of European Committee on Antimicrobial Susceptibility Testing methodology, the analysis of relevant and reliable data correlating different AST tests to patients\u2019 outcomes may yield clinical breakpoints for susceptibility, but these data are currently unavailable. At present, we believe that it is unlikely that standard determination of minimum inhibitory concentration will prove the best predictor.<\/jats:p>","DOI":"10.1093\/ofid\/ofac082","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T14:24:06Z","timestamp":1644848646000},"source":"Crossref","is-referenced-by-count":15,"title":["Establishing Antimicrobial Susceptibility Testing Methods and Clinical Breakpoints for Inhaled Antibiotic Therapy"],"prefix":"10.1093","volume":"9","author":[{"given":"Miquel B","family":"Ekkelenkamp","sequence":"first","affiliation":[{"name":"University Medical Center Utrecht, Department of Medical Microbiology, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"D\u00edez-Aguilar","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal and Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n\u00a0Biom\u00e9dica en\u00a0Red de Enfermedades Infecciosas, Madrid, Spain"},{"name":"Servicio de Microbiolog\u00eda y Parasitolog\u00eda, Hospital Universitario La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M","family":"Tunney","sequence":"additional","affiliation":[{"name":"Queen\u2019s University Belfast, Department of Pulmonology, Belfast, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Stuart","family":"Elborn","sequence":"additional","affiliation":[{"name":"Queen\u2019s University Belfast, Department of Pulmonology, Belfast, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad C","family":"Fluit","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Department of Medical Microbiology, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-3173","authenticated-orcid":false,"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal and Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n\u00a0Biom\u00e9dica en\u00a0Red de Enfermedades Infecciosas, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"2022030716583767200_CIT0001","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis.","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"key":"2022030716583767200_CIT0002","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision.","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2022030716583767200_CIT0003","doi-asserted-by":"crossref","first-page":"101885","DOI":"10.1016\/j.pupt.2019.101885","article-title":"Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis.","volume":"60","author":"Karampitsakos","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"2022030716583767200_CIT0004","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/CMR.00101-15","article-title":"Inhaled antibiotics for gram-negative respiratory infections.","volume":"29","author":"Wenzler","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2022030716583767200_CIT0005","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.cmi.2021.03.019","article-title":"A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram negative pathogens.","volume":"27","author":"Henderson","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022030716583767200_CIT0006","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints.","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2022030716583767200_CIT0007","doi-asserted-by":"crossref","first-page":"118S","DOI":"10.1378\/chest.120.3_suppl.118S","article-title":"Microbiological and immunologic considerations with aerosolized drug delivery.","volume":"120","author":"LiPuma","year":"2001","journal-title":"Chest"},{"key":"2022030716583767200_CIT0008","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/ciz364","article-title":"Antimicrobial resistance international working group in cystic fibrosis. Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections.","volume":"69","author":"Waters","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022030716583767200_CIT0009","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1128\/JCM.43.9.4480-4485.2005","article-title":"Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.","volume":"43","author":"Morosini","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2022030716583767200_CIT0010","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00090314","article-title":"Inhaled antibiotics: dry or wet?","volume":"44","author":"Tiddens","year":"2014","journal-title":"Eur Respir J"},{"key":"2022030716583767200_CIT0011","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/jamp.2008.0693","article-title":"A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers.","volume":"22","author":"Weers","year":"2009","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2022030716583767200_CIT0012","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1378\/chest.124.1.360","article-title":"Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers.","volume":"124","author":"Newhouse","year":"2003","journal-title":"Chest"},{"key":"2022030716583767200_CIT0013","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/CMR.00022-14","article-title":"Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.","volume":"27","author":"Dalhoff","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2022030716583767200_CIT0014","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00134-012-2628-7","article-title":"Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients.","volume":"38","author":"Athanassa","year":"2012","journal-title":"Intensive Care Med"},{"key":"2022030716583767200_CIT0015","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jac\/dki461","article-title":"Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.","volume":"57","author":"Ratjen","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2022030716583767200_CIT0016","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.3390\/jcm9123800","article-title":"Impact of Pseudomonas aeruginosa infection on patients with chronic inflammatory airway diseases.","volume":"9","author":"Garcia-Clemente","year":"2020","journal-title":"J Clin Med"},{"key":"2022030716583767200_CIT0017","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"2022030716583767200_CIT0018","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review.","volume":"18","author":"Somayaji","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2022030716583767200_CIT0019","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.","volume":"179","author":"Burns","year":"1999","journal-title":"J Infect Dis"},{"key":"2022030716583767200_CIT0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcf.2016.10.001","article-title":"The fate of inhaled antibiotics after deposition in cystic fibrosis: how to get drug to the bug?","volume":"16","author":"Bos","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2022030716583767200_CIT0021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MCP.0000000000000557","article-title":"Inhaled antibiotics for the treatment of pneumonia.","volume":"25","author":"Schreiber","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2022030716583767200_CIT0022","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis.","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2022030716583767200_CIT0023","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach.","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2022030716583767200_CIT0024","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/jac\/dkv145","article-title":"The 2014 Garrod Lecture: EUCAST\u2014are we heading towards international agreement?","volume":"70","author":"Kahlmeter","year":"2015","journal-title":"J Antimicrob Chemother"},{"year":"2019","author":"European Committee on Antimicrobial Susceptibility Testing.","key":"2022030716583767200_CIT0025"},{"key":"2022030716583767200_CIT0026","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00276-21","article-title":"Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [manuscript published online ahead of print 4 August 2021].","author":"Giske","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2022030716583767200_CIT0027","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute.","year":"2020","edition":"30"},{"key":"2022030716583767200_CIT0028","doi-asserted-by":"crossref","first-page":"e01541","DOI":"10.1128\/AAC.01541-19","article-title":"Susceptibility of Pseudomonas aeruginosa recovered from cystic fibrosis patients to murepavadin and 13 comparator antibiotics.","volume":"64","author":"Ekkelenkamp","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022030716583767200_CIT0029","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1513\/AnnalsATS.201402-050AS","article-title":"Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.","volume":"11","author":"Chmiel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"author":"European Committee on Antimicrobial Susceptibility Testing.","key":"2022030716583767200_CIT0030"},{"key":"2022030716583767200_CIT0031","volume-title":"Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes","author":"Clinical and Laboratory Standards Institute.","year":"2018","edition":"1"},{"key":"2022030716583767200_CIT0032","first-page":"CD008319","article-title":"Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.","volume":"10","author":"Smith","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2022030716583767200_CIT0033","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.06-2888","article-title":"Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.","volume":"132","author":"Merlo","year":"2007","journal-title":"Chest"},{"key":"2022030716583767200_CIT0034","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000087686","article-title":"Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa.","volume":"73","author":"Lechtzin","year":"2006","journal-title":"Respiration"},{"key":"2022030716583767200_CIT0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcf.2012.03.009","article-title":"Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.","volume":"11","author":"Konstan","year":"2012","journal-title":"J Cyst Fibros"},{"key":"2022030716583767200_CIT0036","doi-asserted-by":"crossref","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J"},{"key":"2022030716583767200_CIT0037","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur Respir J"},{"year":"2021","author":"European Committee on Antimicrobial Susceptibility Testing.","key":"2022030716583767200_CIT0038"},{"key":"2022030716583767200_CIT0039","doi-asserted-by":"crossref","first-page":"e00834","DOI":"10.1128\/JCM.00834-19","article-title":"Antimycobacterial susceptibility testing of nontuberculous mycobacteria.","volume":"57","author":"Brown-Elliott","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2022030716583767200_CIT0040","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.","volume":"51","author":"Brown-Elliott","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2022030716583767200_CIT0041","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cmi.2018.01.003","article-title":"Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?","volume":"24","author":"Coenye","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2022030716583767200_CIT0042","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/1469-0691.12651","article-title":"Antimicrobial susceptibility testing in biofilm-growing bacteria.","volume":"20","author":"Maci\u00e0","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2022030716583767200_CIT0043","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1093\/jac\/dkab222","article-title":"Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates.","volume":"76","author":"D\u00edez-Aguilar","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022030716583767200_CIT0044","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ppul.21350","article-title":"Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.","volume":"46","author":"Moskowitz","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"2022030716583767200_CIT0045","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1016\/j.bmc.2016.11.008","article-title":"Animal models in the pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents.","volume":"24","author":"Zhao","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"2022030716583767200_CIT0046","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jcf.2017.09.001","article-title":"Animal and model systems for studying cystic fibrosis.","volume":"17","author":"Rosen","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2022030716583767200_CIT0047","doi-asserted-by":"crossref","first-page":"29ra31","DOI":"10.1126\/scitranslmed.3000928","article-title":"Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth.","volume":"2","author":"Stoltz","year":"2010","journal-title":"Sci Transl Med"},{"key":"2022030716583767200_CIT0048","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201708-1616OC","article-title":"Infection is not required for mucoinflammatory lung disease in CFTR-knockout ferrets.","volume":"197","author":"Rosen","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2022030716583767200_CIT0049","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S1569-1993(11)60021-0","article-title":"The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease.","volume":"10","author":"Zhou","year":"2011","journal-title":"J Cyst Fibros"},{"key":"2022030716583767200_CIT0050","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1165\/rcmb.2013-0261OC","article-title":"Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets.","volume":"50","author":"Sun","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2022030716583767200_CIT0051","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/17476348.1.1.7","article-title":"MICs, MPCs and PK\/PDs: a match (sometimes) made in hosts.","volume":"1","author":"Hesje","year":"2007","journal-title":"Expert Rev Respir Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac082\/42515632\/ofac082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/4\/ofac082\/42754762\/ofac082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/4\/ofac082\/42754762\/ofac082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T16:59:40Z","timestamp":1646672380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac082\/6528319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac082","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,2,14]]},"article-number":"ofac082"}}